IL269127A - Derivatives of desmetylantol triton for the treatment of diseases related to the generation of reactive oxygen species (ROS) of mitochondrial origin - Google Patents
Derivatives of desmetylantol triton for the treatment of diseases related to the generation of reactive oxygen species (ROS) of mitochondrial originInfo
- Publication number
- IL269127A IL269127A IL26912719A IL26912719A IL269127A IL 269127 A IL269127 A IL 269127A IL 26912719 A IL26912719 A IL 26912719A IL 26912719 A IL26912719 A IL 26912719A IL 269127 A IL269127 A IL 269127A
- Authority
- IL
- Israel
- Prior art keywords
- desmethylanethole
- trithione
- ros
- derivatives
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002438 mitochondrial effect Effects 0.000 title 1
- 239000003642 reactive oxygen metabolite Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762467874P | 2017-03-07 | 2017-03-07 | |
| EP17159691 | 2017-03-07 | ||
| PCT/EP2018/055651 WO2018162581A1 (en) | 2017-03-07 | 2018-03-07 | Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL269127A true IL269127A (en) | 2019-11-28 |
Family
ID=61628329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL26912719A IL269127A (en) | 2017-03-07 | 2019-09-04 | Derivatives of desmetylantol triton for the treatment of diseases related to the generation of reactive oxygen species (ROS) of mitochondrial origin |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11484529B2 (enExample) |
| EP (1) | EP3592348A1 (enExample) |
| JP (1) | JP2020511450A (enExample) |
| KR (1) | KR20190129900A (enExample) |
| CN (1) | CN110662535A (enExample) |
| AU (1) | AU2018232799B2 (enExample) |
| BR (1) | BR112019018495A2 (enExample) |
| CA (1) | CA3055122A1 (enExample) |
| IL (1) | IL269127A (enExample) |
| RU (1) | RU2019131478A (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021003997A2 (pt) * | 2018-09-06 | 2021-05-25 | OP2 Drugs | composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma |
| CN112546216B (zh) * | 2020-11-20 | 2022-10-28 | 西湖大学 | 小分子化合物奥替普拉在制备增强体液免疫应答的药物中的应用 |
| US20240050402A1 (en) * | 2020-12-10 | 2024-02-15 | Frédéric MARIN | Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries |
| WO2022171265A1 (en) * | 2021-02-09 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Modulators of complex i |
| CN114414332B (zh) * | 2022-01-05 | 2024-04-16 | 北京科技大学 | 一种基于Al-CQDs和Al-CNSs的抗氧化剂的制备方法 |
| CN119185368A (zh) * | 2024-09-26 | 2024-12-27 | 中南大学 | 具有线粒体序贯靶向能力的强抗氧化性纳米药物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998027970A2 (en) * | 1996-12-24 | 1998-07-02 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| AU6462500A (en) | 1999-07-29 | 2001-02-19 | Patrick T. Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| KR20030067935A (ko) | 2002-02-09 | 2003-08-19 | 김상건 | 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물 |
| US7076790B2 (en) * | 2000-05-22 | 2006-07-11 | Clarion Co., Ltd. | Disk player |
| CN1355156A (zh) * | 2000-11-27 | 2002-06-26 | 朱国和 | 含有造纸废料污泥的微生物菌肥及其制备方法 |
| CN1244325C (zh) | 2001-05-11 | 2006-03-08 | 成都国嘉联合制药有限公司 | 胆维他在制药中的应用 |
| US7199122B2 (en) | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| JP2005522446A (ja) | 2002-02-13 | 2005-07-28 | ソルベイ・フアルマ | 肺癌の化学予防におけるアネトールジチオールチオンの使用 |
| TW200640898A (en) | 2005-02-24 | 2006-12-01 | Solvay Pharm Bv | Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission |
| EP2125775A4 (en) | 2007-03-01 | 2011-07-13 | Cedars Sinai Medical Center | ANTIOXIDATION POLYMERS WITH [1,2] -DITHIOLANTEILES AND THEIR USE |
| CN102807557B (zh) * | 2012-08-21 | 2015-02-04 | 苏州大学 | 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用 |
| CN102961376B (zh) * | 2012-11-06 | 2015-06-10 | 暨南大学 | HMG-CoA还原酶抑制剂氟伐他汀在制备抗淋巴瘤药物中的应用 |
| CN102961375B (zh) | 2012-12-05 | 2015-01-14 | 苏州大学 | 一种ampk激活剂及其在制备治疗糖尿病和/或糖尿病并发症的药物中的应用 |
-
2018
- 2018-03-07 CA CA3055122A patent/CA3055122A1/en active Pending
- 2018-03-07 US US16/491,617 patent/US11484529B2/en active Active
- 2018-03-07 EP EP18711055.6A patent/EP3592348A1/en not_active Withdrawn
- 2018-03-07 JP JP2019548696A patent/JP2020511450A/ja active Pending
- 2018-03-07 KR KR1020197028579A patent/KR20190129900A/ko not_active Ceased
- 2018-03-07 RU RU2019131478A patent/RU2019131478A/ru unknown
- 2018-03-07 CN CN201880029927.4A patent/CN110662535A/zh active Pending
- 2018-03-07 AU AU2018232799A patent/AU2018232799B2/en not_active Ceased
- 2018-03-07 BR BR112019018495A patent/BR112019018495A2/pt not_active IP Right Cessation
-
2019
- 2019-09-04 IL IL26912719A patent/IL269127A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019131478A3 (enExample) | 2021-07-09 |
| KR20190129900A (ko) | 2019-11-20 |
| BR112019018495A2 (pt) | 2020-04-14 |
| EP3592348A1 (en) | 2020-01-15 |
| AU2018232799B2 (en) | 2021-11-25 |
| JP2020511450A (ja) | 2020-04-16 |
| US11484529B2 (en) | 2022-11-01 |
| AU2018232799A1 (en) | 2019-10-03 |
| US20210154175A1 (en) | 2021-05-27 |
| CN110662535A (zh) | 2020-01-07 |
| CA3055122A1 (en) | 2018-09-13 |
| RU2019131478A (ru) | 2021-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257963B (en) | Compounds for the treatment of diseases related to the production of mitochondrial reactive oxygen species (ros). | |
| IL275321A (en) | Treatment of diseases associated with the expression of DUX4 | |
| ZA201903161B (en) | Antiviral compositions for the treatment of infections linked to coronaviruses | |
| PL3349783T3 (pl) | Kompozycje i sposoby do leczenia chorób | |
| JO3706B1 (ar) | مشتقات H4- بيرولو[2,3-c] بيريدين-4- ون | |
| SG10201908028SA (en) | Cyclopropylamines as lsd1 inhibitors | |
| HUE054389T2 (hu) | Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására | |
| NZ724691A (en) | Quinoline derivatives as smo inhibitors | |
| EP3509636A4 (en) | REDUCTION IN QUANTITIES OR ACTIVITY OF SYSTEMIC REGULATORY T CELLS FOR THE TREATMENT OF CNS ILLNESS AND INJURY | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| EP3122754A4 (en) | Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease | |
| PT3273955T (pt) | Tratamento de doenças respiratórias | |
| EP3097085A4 (en) | Benzoxazinone derivatives for treatment of skin diseases | |
| EA201690936A1 (ru) | Применение цистеамина и его производных для лечения митохондриальных заболеваний | |
| SG11201913817XA (en) | Compounds affecting pigment production and use thereof for treatment of bacterial diseases | |
| MX2016004533A (es) | Derivados de n-cicloalquil-n-(biheterociclilmetilen)-(tio)carboxam ida. | |
| GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
| EP3706727A4 (en) | SMALL MOLECULAR ACTIVE INGREDIENTS AND RELATED METHODS FOR TREATMENT OF DISEASES IN CONNECTION WITH 42 OLIGOM EDUCATION | |
| TN2016000107A1 (en) | Substituted phenylalanine derivatives | |
| EP3285771A4 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| EP3215190A4 (en) | Treatment of neonatal hypoxia including impairments or effects thereof | |
| SI3302499T1 (sl) | Zdravljenje mitohondrijskih bolezni | |
| EP3506906A4 (en) | TOPICAL FORMULATIONS OF FENOLDOPAM FOR THE TREATMENT OF SKIN DISORDERS | |
| PL3079684T3 (pl) | Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna | |
| BR112018004518A2 (pt) | compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais |